Myria Biosciences pioneers GEMMS (Genetically Engineered Modular Molecule Scaffolds), a new class of therapeutic molecules that combines the most important features of small molecules and biologics, the two work horses of the pharmaceutical industry, into one. Myria’s platform uses computational data mining, synthetic biology and high-throughput experimentation to design, produce and test millions of novel molecules, and provides innovative drug candidates for diseases where other drugs have failed to deliver.
